XBiotech Inc. (XBIT)

NASDAQ: XBIT · USD

$1.96

+0.11 (+6.0%)· Recorded snapshot

Market cap	59.8M
Net income (ttm)	-45.1M
EPS (ttm)	-$1.48
Shares out	30.5M
Volume	303,841
Beta	0.80

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -45.1M
EPS (ttm): -$1.48
Market cap: 59.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ホールド

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-29.9

P25 -113.8P50 -46.5P75 -0.9

ROIC-250.5

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All XBIT indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001626878
Company name	XBiotech Inc.
Country	United States
Country code	US
CUSIP number	98400H102
Earnings date	2026-11-11
Employees	87
Employees change	-3
Employees growth	-3.33%
Enterprise value	$-49.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2005
Industry	Biotechnology
IPO date	2015-04-15
Is primary listing	Yes
Is SPAC	No
ISIN number	CA98400H1029
Last 10-K release date	2026-03-13
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$59.8M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$1.96
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	XBIT
U.S. state	Texas
Website	https://www.xbiotech.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-75.53%
FCF / EV yield	76.87%
FCF yield	-72.41%
P/B ratio	0.44x
Price / tangible book value	0.44x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-518,770
ROA	-19.3%
ROA (5Y)	-11.12%
ROCE	-37.01%
ROE	-29.94%
ROE (5Y)	-15.34%
ROIC	-250.55%
ROIC (5Y)	-176.1%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-144,000
Depreciation and amortization	$1.4M
EBIT	$-48.2M
EBITDA	$-46.8M
EPS	$-1.48
FCF per share	$-1.34
Free cash flow	$-40.8M
Free cash flow minus SBC	$-41.4M
Income taxes	$273,000
Investing cash flow	$-139,000
Net cash flow	$-43.4M
Net income	$-45.1M
Operating cash flow minus SBC	$-41.2M
Operating income	$-48.2M
Stock-based compensation	$530,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.21
Debt / equity	0
Long-term assets	$22.5M
Long-term liabilities	$1.8M
Net cash (debt)	$109.5M
Net cash / market cap	194.19%
Net cash growth	-28.38%
Net debt / equity	-0.85
Piotroski F-Score	1
Property, plant and equipment	$22.5M
Shareholders' equity	$128.5M
Tangible book value	$128.5M
Tangible book value per share	$4.21
Total assets	$133.7M
Total cash	$109.5M
Total debt	$0
Total liabilities	$5.2M
WACC	8.62%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$111.2M
Current liabilities	$3.4M
Current ratio	33.15
Net working capital	$-1.7M
Quick ratio	32.75
Working capital	$107.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.04%
Dividend per share	$0.00
Dividend yield	0%
Last dividend	$2.47
Shareholder yield	-0.04%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-85.62%
10Y return CAGR	-16.41%
10Y total return	-83.34%
150-day SMA	$2.30
1D price change	5.95%
1M price change	-8.76%
1M total return	-8.76%
1W price change	-1.98%
1W total return	-1.98%
1Y price change	-22.96%
1Y return CAGR	-22.97%
1Y total return	-22.96%
20-day SMA	$2.09
200-day SMA	$2.33
3M price change	-12.39%
3M total return	-12.39%
3Y price change	-50.5%
3Y return CAGR	-20.89%
3Y total return	-50.5%
50-day SMA	$2.17
50-day SMA vs 200-day SMA	50under200
52-week high	$3.44
52-week high date	2025-11-11
52-week low	$1.80
52-week low date	2026-10-28
5Y price change	-86.02%
5Y return CAGR	-32.53%
5Y total return	-86.02%
6M price change	-23.11%
6M total return	-23.11%
All-time high	$32.50
All-time high date	2015-04-21
All-time low	$1.80
All-time low date	2026-10-28
Average true range (ATR)	$0.10
Average volume	86.1K
Beta (1Y)	0.62
Beta (2Y)	1.12
Beta (5Y)	0.8
Change from 52-week high	-43.02%
Change from 52-week low	8.89%
Change from all-time high	-93.91%
Change from all-time low	10%
Change from open	5.95%
Day's gap	0%
Dollar volume	$595,528
High price	$2.00
Low price	$1.82
Monthly RSI	36.47
Open price	$1.85
Position in 52-week range	77.78%
Premarket change	6.49%
Premarket close	$1.85
Premarket price	$1.97
Premarket volume	200
Previous close	$1.85
Price vs 150-day SMA	-14.03%
Price vs 20-day SMA	-5.44%
Price vs 200-day SMA	-15.06%
Price vs 50-day SMA	-8.67%
Relative volume	3.53
RSI	40.11
Sharpe ratio	-0.45
Sharpe ratio (3Y)	-0.08
Sharpe ratio (5Y)	-0.35
Sortino ratio	-0.58
Sortino ratio (3Y)	-0.03
Sortino ratio (5Y)	-0.42
Volume	303.8K
Weekly RSI	33.48
YTD price change	-17.15%
YTD total return	-17.15%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19M
Float percentage	62.37%
Shares change (QoQ)	0%
Shares change (YoY)	0.04%
Shares held by insiders	37.63%
Shares held by institutions	6.71%
Shares outstanding	30.5M
Short % of float	1.73%
Short % of shares	1.08%
Short ratio	6.3 days

Deeper analysis on XBIT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XBIT report

Is a complete XBIT research report available?

No complete published report is available for XBiotech Inc. (XBIT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

XBiotech Inc. (XBIT)

Price

Financial snapshot

Fair-value bridge

Latest news · XBIT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XBIT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XBIT

Frequently asked questions